Viz.ai has unveiled plans to use its Viz RECRUIT platform for optimising the enrolment of participants in the NIH-funded Pulmonary Embolism-Thrombus Removal with Catheter-Directed Thrombolysis (PE-TRACT) clinical trial.
The randomised, open-label, assessor-blinded PE-TRACT trial has been designed to compare catheter-directed therapy (CDT) and anticoagulation (CDT group) with anticoagulation alone (No-CDT) in submassive pulmonary embolism (PE), proximal pulmonary artery thrombus, and right ventricular dilation patients.
It will address whether CDT needs to be routinely used for the treatment of intermediate-risk PE compared to anticoagulants alone.
A total of 500 participants across 30 to 50 sites are planned to be enrolled in the trial.
In the trial, the participating research institutions will use the artificial intelligence (AI)-powered clinical trial enrolment platform, Viz RECRUIT, for finding, screening, and enrolling candidates in the clinical trial.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
The platform automates the identification of eligible candidates for pre-trial review and also reduces the burden on the research team.
In addition to streamlining the trial enrolment workflow, the Cloud-based technology also helps broaden the recruitment funnel in size and diversity.
The clinical trial sites will be able to automatically screen participants based on PE and high right ventricular to left ventricular diameter (RV/LV) ratio using the Viz RECRUIT platform.
Viz.ai chief clinical officer Jayme Strauss said: “With our platform’s real-world accuracy and demonstrated success, researchers can use AI to identify potentially eligible trial candidates, regardless of their location, ultimately expediting the clinical trial enrolment process.
“We aim to expand the participation and diversity of participants in clinical research to make treatments safer for all patients and advance the development of novel treatments while empowering research teams to efficiently and consistently screen for patients and coordinate research.”